论文部分内容阅读
目的:探讨(99m)~Tc-MIBI三维立体显像对肺癌患者的临床应用价值。方法:对30例肺占位病变的患者,采用PHILIPS公司FORTE-AZ SPECT仪进行采集,配以低能高分辨准直器。均行(99m)~Tc-MIBI早期和延迟肺显像,断层采集矩阵64×64,每帧40 s,zoom 1.5,采集64帧,获得三维影像并进行三维动态显示;同时,测定病变靶/非靶摄取比值和肿瘤滞留指数。结果:研究结果表明,三维显示对诊断肺部恶性病变优于平面显像法,其灵敏度90.0%,特异性80.0%,准确率86.6%。肺良性病变患者早期及延迟显像的病变靶/非靶摄取比值分别为1.19±0.27和1.13±0.19;肺癌患者分别为1.49±0.23和1.45±0.21,肿瘤滞留指数>0。肺癌化疗前早期显像和延迟显像的病变靶/非靶摄取比值和肿瘤滞留指数均明显高于治疗后的相应值。结论:(99m)~Tc-MIBI三维立体显像法可提高肺癌阳性显像的分辨力,更好地进行空间定位,提高肺癌原发病灶及其在相邻的部位转移灶检出率,是一项实用性较强的肺癌辅助检查手段。同时也是监测肺癌复发与评价肺癌化疗效果的有效方法。
Objective: To investigate the clinical value of (99m) ~ Tc-MIBI three-dimensional imaging in patients with lung cancer. Methods: Thirty patients with lung lesions were collected by PHILIPS FORTE-AZ SPECT instrument and equipped with low energy and high resolution collimator. (99m) ~ Tc-MIBI early and delayed lung imaging, the acquisition matrix 64 × 64, each frame 40 s, zoom 1.5, collecting 64 frames to obtain three-dimensional images and three-dimensional dynamic display; the same time, Non-target uptake ratio and tumor retention index. Results: The results show that the three-dimensional display is superior to plain imaging in the diagnosis of lung malignant lesions. The sensitivity is 90.0%, the specificity is 80.0% and the accuracy is 86.6%. The ratio of target / non-target uptake in early and delayed imaging of benign lung diseases were 1.19 ± 0.27 and 1.13 ± 0.19, respectively. The lung cancer patients were 1.49 ± 0.23 and 1.45 ± 0.21 respectively, and the tumor retention index was> 0. The target target / non-target uptake ratio and tumor retention index of early stage imaging and delayed imaging of lung cancer before chemotherapy were significantly higher than the corresponding values after treatment. Conclusion: (99m) ~ Tc-MIBI three-dimensional imaging can improve the resolution of lung cancer positive imaging, make better spatial location, and improve the detection rate of primary lung cancer and its adjacent metastasis sites. A practical method of lung cancer aids. It is also an effective method to monitor the recurrence of lung cancer and evaluate the effect of chemotherapy for lung cancer.